Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | rHuPH20 |
Trade Name | |
Synonyms | Hylenex |
Drug Descriptions |
rHuPH20 is recombinant human hyaluronidase lacking the GPI anchor domain, which may enhance dispersion of substances delivered subcutaneously (PMID: 25967925, PMID: 16876899, PMID: 30744432). |
DrugClasses | |
CAS Registry Number | 757971-58-7 |
NCIT ID | C61504 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Amivantamab-vmjw + Lazertinib + rHuPH20 | Amivantamab-vmjw Lazertinib rHuPH20 | 0 | 1 |
Amivantamab-vmjw + rHuPH20 | Amivantamab-vmjw rHuPH20 | 0 | 1 |
Atezolizumab + rHuPH20 | Atezolizumab rHuPH20 | 0 | 2 |
Daratumumab + Lenalidomide + rHuPH20 | Daratumumab Lenalidomide rHuPH20 | 0 | 1 |
Daratumumab + rHuPH20 | Daratumumab rHuPH20 | 0 | 2 |
Ipilimumab + Nivolumab + rHuPH20 | Ipilimumab Nivolumab rHuPH20 | 0 | 1 |
Nivolumab + Relatlimab + rHuPH20 | Nivolumab Relatlimab rHuPH20 | 0 | 2 |
Nivolumab + rHuPH20 | Nivolumab rHuPH20 | 0 | 2 |
rHuPH20 | rHuPH20 | 0 | 0 |